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[571 ABSTRACT 
A screening assay for detecting the presence of Pseudo- 
monas bacteria in a test sample comprising isolating the 
bacteria present in the sample, extracting Azurin pro- 
tein from the periplasm within the bacteria, reacting the 
extract with an enzymatically labelled, Azurin-specific 
antibody and a color-producing substrate specific for 
the enzyme which is capable of producing a color dis- 
tinct from the color generated by Azurin and reading 
the results of the reaction of the sample with the anti- 
body to determine whether the color has been produced 
whereby the presence of Pseudomonas bacteria in the 
sample is indicated. 
15 Claims, No Drawings 
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to be inaccurate and unreliable since it results in fre- 
quent false positive and false negative readings. 
In addition to the aforementioned method, there also 
have been other previous attempts to create probes for 
PSEUDOMONAS SCREENING ASSAY 
ORIGIN OF THE INVENTION -~ ~~ 
5 the rapid and inexpensive detection of Pseudomonas 
bacteria. However, to date, none of these probes have 
proven sufficiently specific for clinical utilization. 
STATEMENT O F  THE INVENTION 
The invention described herein was made in the per- 
formance of work under a NASA contract, and is sub- 
ject to the provisions of Public Law 96-517 (35 USC 
202) in which the Contractor has elected not to retain 
titid. 10 The present invention provides a solution to the time, 
cost and reliability problems in the detection of Pseudo- 
monas bacteria. Specifically, the present invention is 
This invention relates to a method or test for the directed to a diagnostic assay for pseudomonas bacteria 
detection Of Pseudomonas bacteria. More particularly, which is simple and inexpensive to perform. Contrast 
the invention relates to a Pseudomonas diagnostic assay 15 to prior procedures, the method ofthe present invention 
involving the use of an Azurin-SPecific monoclonal significantly reduces the time required to diagnose the 
antibody or antiserum for detection of the marker Am- bacteria and provides accurate and reliable test results. 
rin in Pseudomonas bacteria. The foregoing is achieved by a process which in- 
volves the use of Azurin, a blue, copper-containing 
20 monomeric Drotein sDecificallv found in the Pseudomo- DISCUSSION OF THE PRIOR ART 
TECHNICAL FIELD 
The development of new diagnostic procedures for 
the rapid, accurate and cost efficient detection of the 
presence of bacteria which cause infection in suscepti- 
ble hosts is a continuing concern for medical practitio- 
ners. For example, the early detection of the presence of 
Pseudomonas bacteria in a patient’s system is particu- 
larly critical since strains of this bacteria are known to 
cause a large repertoire of virulent infections exhibiting 
high intrinsic resistance to antibiotic therapy and which 
demonstrate an adverse prognosis for cure if treatment 
is not initiated at as early a stage as possible. Exemplary 
of diseases associated with the Pseudo-monas bacteria 
are “Legionnaire’s Disease”, gram-negative septicemia 
and terminal lung disease in patients with cystic fibrosis. 
These infections spread extremely rapidly through-out 
a host’s system once the bacteria is introduced therein. 
Accordingly, commencement of treatment at as early a 
stage as possible and, particularly, the early administra- 
tion of a mixture of highly aggressive antibiotics is es- 
sential to thwart the spread of the disease. 
nas bacteria, as a specific marker for the immunological 
diagnosis of the presence of the Pseudomonas bacteria. 
More particularly, it has been found that Azurin can be 
readily extracted from the periplasm of Pseudomonas 
25 bacteria by a simple procedure. After extraction, the 
Azurin protein can be reliably, accurately and rapidly 
identified by treating a sample containing Azurin with 
an Azurin-specific monoclonal antibody or antiserum as 
tested in an enzyme-linked immunosorbent assay 
Thus, in accordance with the present invention, the 
presence of Pseudomonas bacteria in a sample culture 
taken from the body fluids such as the mucus, urine, 
saliva, blood or an abscess of a patient can be conclu- 
35 sively established by treating the test sample to extract 
any Azurin present therein and applying the Azurin 
antiserum to identify whether any Azurin is actually 
present in the sample. From this diagnostic test, a posi- 
tive indication of the presence of Azurin will establish 
40 the presence of the Pseudomonas bacteria whereas a 
30 (ELISA). 
negative showing will demonstrate that the bacteria is 
Thus, it is especially important that the presence of not present. 
the Pseudomonas bacteria in a host be reliably diag- process for extracting and diagnosing nosed at the earliest possible time so that appropriate the presence of pseudomonas bacteria utilizing Azurin 
treatment can be initiated immediately. Ideally, the 45 as a marker therefor generally comp,.jses the steps of: 
diagnostic analysis of a specimen potentially carrying (1) obtaining a test body fluid sample from a patient and 
the same day it is taken from a Patient to enable such a shock treating the precipitate with water for the pur- 
rapid treatment schedule. Present tests must be con- pose of extraction of ~ ~ ~ r i ~  from the periplasm; (3) 
ducted by outside laboratories. It would be Preferable 50 short s p h i n g  of the mixture to separate k u r i n  in the 
to have a simple kit containing all the necessary rea- supernatant; (4) transferring a drop from (3) to a nitro- 
gents for conducting the test within the physician’s cellulose membrane and incubating the membrane in a 
office. primary antibody solution (Anti-Azurin antibody); (5) 
However, existing methods for detecting PSeudomo- preparing the membrane for enzymatic staining (wash) 
nas bacteria have been found to be relatively tedious 55 and (6) staining the membrane and reading the results to 
and time consuming which precludes immediate diag- determine whether Pseudomonas bacteria were present 
nosis. Furthermore, the prior techniques have been in the test sample as evidenced by the presence of Azu- 
found to be rather inaccurate and unreliable as well as 
being expensive to perform. Specifically, the standard The primary antibody solution (Anti-Azurin anti- 
method for detection of Pseudomonas bacteria h d v e s  60 body) for use in this process may be prepared in actor- 
growing the bacteria on an agar plate, treating a poly- dance with the method disclosed by A.B. Champion et 
saccharide capsule contained within the bacteria with al. in an article entitled “Immunological Comparison of 
reagent and reading the growth of the bacteria visually. Azurins of Known Amino Acid Sequence” which ap- 
This approach is relatively costly to perform and has peared in J. Mol. Evol. 5, 291-305 (1975). The method 
been found to require a longer than desirable period of 65 disclosed therein involved immunizing New Zealand 
time to detect the presence of the bacteria which delays white rabbits with purified Azurin for a period of 5 to 6 
the commencement of the necessary antibiotic treat- months. The AzuM may be initially obtained from 
merit. The previously standard test also has been found aerobic bacteria such as Pseudomonas Auroginosa. 
The 
the bacteria should be capable of being completed on spinning it down to isolate the bacteria therein; (2) 
in the sample. 
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Generally, several white rabbits are immunized to com- The procedure of the preferred embodiment is com- 
pensate for the problem of anti-serum variability. Each pleted with an enzymatic immunostaining of the mem- 
rabbit receives between 0.2 and 1.0 mg of Azurin per brane. In this regard, the enzyme used was horseradish 
injection. An initial intradermal back injection is made peroxidase and the color developing reagent was 4- 
with Freund's complete adjuvant which is supple- 5 chloro-1-napthol (Sigma) in ethanol (3 mg/ml) formu- 
merited with 4 mg/ml ]yophized phenol-killed BCG lated into a Tris-buffered saline solution as follows: 
cells and the Azurin preparation is mixed in the (v/v) 14.40 ml of water; 1.60 ml of tromethamine (Tris) hav- 
ration of l . l / l ,  respectively. ing a pH of 7.6; 120 pl of 3% H202 and 4.0 ml4-chlo-ro- 
After 10 to 12 weeks another intradermal injection is I-Napthol (Sigma) in ethanol which is stored at -20' C. 
made with Freund's incomplete adjuvant. About 20 to 10 The nitrocellUlOSe membrane is stained by gently shak- 
25 weeks subsequently to the last injection, a series of ing it in the SOlUtiOn for approximately tWO minutes. 
three intravenous injections are made a day apart in the The staining reaction is terminated by placing the mem- 
rabbits' marginal ear vein. The rabbits are then bled one brane in water for One minute- 
week after the last injection. Heparin solution that uti- After the staining Process, the nitrocellulose mem- 
lizes an isotis buffer is added in the amount of 1.0 15 brane is examined to determine whether any Pseudomo- 
per looo units/ml to each 40 ml of rabbit blood col- nas bacteria are present based on the detection of the 
lected to prevent coagulation. It is common practice in 
wme laboratories to use plasma instead of Serum as the 
presence Of the Azurin marker. In this regard, the de- 
velopment Of a represents a positive result 
source of antibodies. Plasma and antiserum behave simi- 
larly in micro-complement fixation tests. 
The heparin-rabbit blood solution is then centrifuged 
at 5000xg for 15 minutes to remove blood cells. The 
supernatant that results from this centrifugation is 
rabbit complement. The treated solution is again centri- 
fuged at 30'000xg for 2o minutes' The 
solution (antiserum) resulting from this centrifugation is 
stored at -10" C. 
indicative of the presence of the Azurin protein which 
20 conclusively establishes the presence of Pseudomonas 
bacteria in the test sample. 
From the foregoing, it will be appreciated that the 
present invention provides a significant improvement in 
test procedures for the detection of Pseudomonas bac- 
expedited results with greatly enhanced accuracy in 
diagnosing the presence of this bacterial strain in a test 
sample taken from a patient. Particularly, it has been 
found that the use of a monoclonal antibody specific to 
An indication that the rabbit antiserum is pure is 30 the Azurin protein enabled the rapid screening of the 
able results which correlated well with those obtained 
utilizing ~mmuno~uorescence staining and chemical 
While there has been what is at present considered to 
be the preferred embodiment of this invention, it will be 
understood that various modifications may be made 
therein and it is intended to Cover in the appended 
heated at 60" c. for 25 minutes to destroy the native 25 teria. will k noted, the present method enables 
shown by a sing1e precipitin arc that appears Pseudomonas bacterial strains with accurate and reli- 
immuno-diffusion tests. Moreover, both pure Azurin 
and Azurins present in crude extracts give identical 
complement fixation curves. labeling techniques. 
EXAMPLE 
In a Preferred embodiment exemplifying the present 
invention, a body fluid sample Of - 10 ml is taken from 
the urine or 
strains in the sample are grown for 0-2 hours at room 40 and scope of the invention, 
temperature until turbidity is noticed. I claim: 
Subsequent to the incubation of the Patient fluids, the 1. A screening assay for detecting the presence of 
resulting bacteria cells are harvested by CentrifUgatiOn Pseudomonas bacteria in a test sample comprising iso- 
in an ePpendorf (microfuge) spin at a rate of  out lating the bacteria present in said sample, extracting 
10,000-15,000 Xg for 0.5 minutes at rpOm temperature. 45 Azurin protein from periplasm within the bacteria in 
Following centrifugation, the Pellet 1s resuspended by said sample, reacting said extract with an enzymatically 
gentle mixing in 1 ml Of distilled Water. The Cells are labelled, Azurin-specific antibody and a color-produc- 
then centrifuged again for 3'minUteS in the miCrOfUge. ing substrate specific for wid enzyme and capable of 
After this centrifugation step, an aliquot (10 PI) of the producing a color distinct from the color generated by 
supernatant is transferred by pipet to the nitrocelhlose 50 Azurin and reading the results of said reaction of said 
membrane for immunological detection. sample with said antibody to determine whether said 
The immunochemical detection of protein on the color has been produced whereby the presence ofpseu- 
nitrocellulose membrane is accomplished by blocking &monas bacteria in said sample is indicated, 
the free binding sites on the membrane for 15 minutes 2. The diagnostic assay of claim 1 wherein said anti- 
with 3% bovine serum albumin and washed with water. 55 body is derived from rabbits or goats immunized with 
The membrane is then incubated 1-2 hours at room Azurin. 
temperature without shaking in primary monoclonal 3. The diagnostic assay of claim 1 in which said anti- 
Anti-Azurin antibody solution which comprises 20 ml 
of 3% BSA/H20 and 50 pl of Anti-Azurin. 4. The screening assay of claim 1 wherein said test 
washed twice at room temperature with PBS or H20 5. The diagnostic assay of claim 4 wherein the body 
for fifteen minute intervals. The membrane is then incu- fluid is selected from the group consisting of urine, 
bated at room temperature without shaking for 1-2 blood, or pus of the patient. 
hours in secondary antibody solution which comprises 6. The screening assay of claim 1 wherein said hac- 
20 ml of 0.5% BSA/H2 and 40 pl of serum. The serum 65 teria in said sample are directly isolated by centrifuga- 
comprises peroxidase anti-rabbit IgG antibody from tion when said sample exhibits turbidity, or incubating 
Miles Scientific. The membrane is then washed at room said sample for up to 2 hours prior to said centrifugation 
temperature in a shaker with H2O for fifteen minutes. until turbidity is evident. 
35 
Of a patient and any Pseudomonas claims all such modifications as fall within the true spirit 
body is a monoclonal antibody. 
Subsequent to the incubation, the membrane is 60 sample is a body fluid of a patient. 
5 
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7. The diagnostic assay of claim 6 wherein said anti- 
body for reacting with said sample is derived from 
rabbits or goats immunized with Azurin. 
8. The diagnostic assay of claim 6 wherein the pres- 
ence of said Azurin extracted from said bacteria in said 
sample is detected by immobilizing said extracted Azu- 
rin on a membrane, blocking free binding sites on the 
membrane and reacting said membrane with said anti- 
9. The diagnostic assay of claim 8 wherein said mem- 
5 
body. 10 
brane is nitrocellulose. 
9 
6 
immobilizing the resulting Azurin extracted from said 
sample on a membrane; 
contacting the membrane with an Azurin-specific, 
enzymatically labelled antibody solution; and 
reacting the antibody with a color-producing sub- 
strate specific for said enzyme and capable of de- 
veloping a color distinct from that of Azurin and 
reading the results to determine whether Pseudo- 
monas bacteria were present in the test sample as 
evidenced by the presence of said color on the 
membrane. 
12. The method of claim 11 in which the membrane is 
10. The diagnostic assay of claim 9 wherein horserad- 
ish peroxidase is employed as an enzyme for said enzy- 13. The method of claim 11 wherein said test body 
matic labelling and 4-chloro-l-napthol in a Tris-buff- 15 fluid sample is selected from the group consisting of 
ered saline solution is utilized as said color developing 14. The method of claim 11 wherein horseradish 
peroxidase is employed as an enzyme for labelling said substrate. 
ence of Pseudomonas bacteria utilizing Azurin as a 20 line solution is % color developing sub- 
marker for said bacteria comprising; 
15. A method according to claim 11 in which the 
nitrocellolose. 
Or pus Of the patient. 
11* A method for screening a body fluid for the pres- antibody and 4-chloro-l-napthol in a Tfis-buffered sa- 
strate. 
antibody is a monoclonal antibody. 
obtaining a test body fluid sample from a patient; 
centrifuging said sample to isolate the bacteria therein 
and extracting the Azurin from said bacteria; * * * * *  
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